Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Greg Fitt

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Cancer|July 6, 2017
The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET)Kathryn M Field, Pramit M Phal, Greg Fitt, et al.
Epilepsia|July 7, 2026
Epileptogenic lesions in the Australian epilepsy project: A harmonized 3-T magnetic resonance imaging protocol and its diagnostic yieldDavid N Vaughan, David F Abbott, Amanda Anderson, et al.
Asia-Pacific Journal of Clinical Oncology|November 9, 2017
Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trialKathryn M Field, Greg Fitt, Mark A Rosenthal, et al.
Neuro-Oncology|July 2, 2015
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastomaKathryn M Field, John Simes, Anna K Nowak, et al.
BMJ Open|August 4, 2023
[<sup>18</sup>F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trialEng-Siew Koh, Hui K Gan, Clare Senko, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 10, 2023
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06Nathaniel Barry, Roslyn J Francis, Martin A Ebert, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Cancer|July 6, 2017
The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET)Kathryn M Field, Pramit M Phal, Greg Fitt, et al.
Epilepsia|July 7, 2026
Epileptogenic lesions in the Australian epilepsy project: A harmonized 3-T magnetic resonance imaging protocol and its diagnostic yieldDavid N Vaughan, David F Abbott, Amanda Anderson, et al.
Asia-Pacific Journal of Clinical Oncology|November 9, 2017
Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trialKathryn M Field, Greg Fitt, Mark A Rosenthal, et al.
Neuro-Oncology|July 2, 2015
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastomaKathryn M Field, John Simes, Anna K Nowak, et al.
BMJ Open|August 4, 2023
[<sup>18</sup>F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trialEng-Siew Koh, Hui K Gan, Clare Senko, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 10, 2023
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06Nathaniel Barry, Roslyn J Francis, Martin A Ebert, et al.
Pageof 2